Evoq Remedies Ltd
₹
- close price
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Advance from Customers Rs. Lakhs ・Standalone data |
|
||||
| Inventory (Stock-in-Hand) Rs. Lakhs ・Standalone data |
|||||
| Purchases of Stock-in-Trade Rs. Lakhs ・Standalone data |
|||||
| Sales Commission Income Rs. Lakhs ・Standalone data |
|||||
| Trade Receivables Rs. Lakhs ・Standalone data |
|||||
| Export Order Secured Rs. Crores ・Standalone data |
|||||
Requires Premium
Requires Premium
Documents
Announcements
-
Closure of Trading Window
30 Mar - Trading window closed from 1 April 2026 until 48 hours after audited results for half-year/year ended 31 March 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Jan - Submitted RTA certificate under Reg 74(5) for quarter ended 31 Dec 2025 (EVOQ, 543500)
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 24 Oct 2025
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Oct 2025
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Oct 2025
Business Overview:[1]
EVOQRL deals in the trading of the pharma
products and commission agent in pharma products, etc.